Skip to main content

Advertisement

Table 1 Demographic, clinical and angiographic data at baseline and in-hospital characteristics of study cohort

From: C-terminal fragment of agrin (CAF) levels predict acute kidney injury after acute myocardial infarction

Variable Study Cohort (n = 403)
Age, years 62 (13)
Age > 70 years, n(%) 132 (33)
BMI, Kg/m2 28 (4)
BSA, m2 a 1.97 (0.2)
Male/Female, n(%) 314 (78) / 89 (22)
Risk Factors
 Hypertension, n(%) 226 (56)
 Diabetes mellitus, n(%) 104 (26)
 Dyslipidemia, n(%) 161 (40)
 Current smokers, n(%) 219 (54)
Co-morbidities
 Previous MI, n(%) 65 (16)
 Chronic heart failure, n(%) 6 (1.5)
 Peripheral arterial disease, n(%) 22 (6)
 Previous stroke or TIA, n(%) 31 (8)
Atrial fibrillation, n(%)  
 Paroxysmal 7 (1.5)
 Chronic 14 (4)
Valvular disease, n(%) 5 (1)
Previous PCI, n(%) 45(11)
Previous CABG, n(%) 10 (2.5)
Anemia, n(%) 66 (16)
Laboratory Data
 Glucose at admission, mg/dl 153 (70)
 Hematocrit at admission, % 42 (5)
 Hemoglobin at admission, g/dL 14.2 (1.7)
 Baseline creatinine, mg/dL 0.98 (0.25)
 Creatinine at 48 h, mg/dL 1.03 (0.31)
 Peak Creatinine during hospitalization, mg/dL 1.12 (0.47)
 Baseline eGFR, mL/min b 94 (35)
 eGFR at 48 h, mL/min b 91 (38)
 Lowest eGFR during hospitalization, mL/min b 85 (33)
 Baseline eGFR classification, n(%)  
  >90 ml/min 199 (49)
  60-90 ml/min 142 (35)
  <60 ml/min 62 (16)
Ejection fraction during hospitalization, n(%)  
 Normal (>55%) 230 (57)
  Mildly reduced (45-55%) 106 (26)
  Moderately reduced (35-44%) 60 (14.5)
  Severely reduced (<35%) 7 (1.5)
Total Cholesterol, mg/dL 204 (49)
LDL Cholesterol, mg/dL 129 (43)
HDL Cholesterol, mg/dL 44 (18)
Triglycerides, mg/dL 155 (98)
CPK at admission, IU/L 201 (106-566)
CK-MB at admission, IU/L 32 (19-62)
Peak CPK during hospitalization, IU/L 1130 (400-2001)
Peak CK-MB during hospitalization, IU/L 91 (37-179)
Peak CRP during hospitalization, mg/dL 4.3 (1.45-8.90)
Hospitalization Data
 Type of Acute Coronary Syndrome
   STEMI, n(%) 288 (71)
   NSTEMI, n(%) 115 (29)
 Site of MI
   Inferior, n(%) 129 (32)
    Anterior, n(%) 169 (41.5)
   Lateral, n(%) 42 (10)
   Infero-lateral, n(%) 13 (3.5)
   Antero-lateral, n(%) 47(11.5)
    Posterior, n(%) 3 (1.5)
Heart rate at admission, bpm 80 (18)
Systolic BP at admission, mmHg 135 (26)
Diastolic BP at admission, mmHg 78 (12)
Low BP (<90 mmHg) at admission, n(%) 20 (5)
Time from symptom onset, hours 6.5 (2-11)
TIMI risk score, n 3 (1-4)
 Killip class, n(%)
   Class I 368 (91)
   Class II 24 (6)
    Class III 8 (2)
    Class IV 3 (1)
 Coronary artery disease, n(%)
  Non-significant disease 17 (4)
   1-vessel 218 (54)
   2-vessel 103 (25)
   3-vessel 65 (17)
  Left main stem disease 25 (6)
 ACS treatment strategy, n(%)  
   Invasive during hospitalization 261 (65)
  Primarily conservative 142 (35)
 IV treatment with, n(%)
   Thrombolysis 172 (42)
    GP IIb/IIIa inhibitors 50 (12.5)
  β-blockers 38 (9.5)
   Use of inotropic support
(catecholamine use or balloon counterpulsation)
17 (4)
   Diuretics 27 (6)
   Anti-arrhythmics 48 (11.5)
Adverse events, n(%) 96 (23)
 Recurrent ischemia 20 (5)
 Re-infarction 14 (3.5)
 Hemodynamic collapse [9] 16 (4)
 Tachyarrhythmia requiring intervention 38 (9.5)
 Bradyarrhythmia requiring intervention 13 (3.5)
 Acute heart failure during hospitalization 31 (7)
 Major bleeding complications [10] 3 (1)
 Acute mitral valve regurgitation (severe) 4 (1)
 Pericarditis 3 (1)
Hospitalization (days) 5 (4-7)
Prior Medication Use
 ACE- inhibitors, n(%) 128 (31)
 Angiotensin receptor blockers, n(%) 89 (22)
 Diuretics, n(%) 65 (16)
 Aldosterone antagonists, n(%) 18 (4)
 Nitrates, n(%) 36 (8)
 Digitalis, n(%) 11 (2.5)
 β- blockers, n(%) 123 (30.5)
 Calcium channel blockers, n(%) 43 (10)
 Amiodarone, n(%) 15 (3.5)
 Statins, n(%) 164 (40)
 Fibrates, n(%) 1 (0.2)
 Aspirin, n(%) 115 (28)
 P2Y12 antiplatelets, n(%) 108 (26)
 Anticoagulants, n(%) 9 (2)
 Anti-diabetics, n(%) 55 (13)
 Metformin, n(%) 35 (8)
 Insulin, n(%) 16 (4)
  1. Values are expressed as means (with the corresponding standard deviation) or medians (with the corresponding interquartitile range) for continuous variables, and as numbers of patients and percentages for categorical variables
  2. ACE angiotensin converting enzyme, BMI body mass index, BP blood pressure, CABG coronary artery bypass graft surgery, CK-MB creatinine kinase myocardial fraction, CPK creatine phosphokinase, CRP C-reactive protein, eGFR estimated glomerular filtration rate, GP glycoprotein, HDL high density lipoprotein, IV intravenous, MI myocardial infarction, NSTEMI non ST elevation myocardial infarction, LDL low density lipoprotein, CAF C- terminal agrin fragment levels, Cyst-C cystatin-C, IL-18 interleukin-18, NGAL neutrophil gelatinase-associated lipocalin, PCI, percutaneous coronary intervention, STEMI ST elevation myocardial infarction, TIA transient ischemic attack, TIMI Thrombolysis in myocardial infarction
  3. aCalculated using the Mosteller formula
  4. bCalculated using the Cockcroft-Gault formula